---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-302552"
form_type: "8-K"
ticker: "LCTX"
cik: "0000876343"
company_name: "Lineage Cell Therapeutics, Inc."
filed_at: "2025-11-28T23:59:59+00:00"
generated_at: "2026-05-16T16:19:35.953382+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Lineage withdraws CIRM grant app for OPC1; plans resubmission Jan 2026

## Summary
- Withdrew CIRM CLIN2 grant application on Nov 28 after receiving CIRM comments on Nov 24.
- No content deficiencies identified; intends to submit revised application in next CIRM cycle (Jan 2026).
- Withdrawal does not impact ongoing DOSED clinical study of OPC1 for spinal cord injury.

## SEC filing metadata
- accession: 0001193125-25-302552
- form_type: 8-K
- ticker: LCTX
- cik: 0000876343
- company_name: Lineage Cell Therapeutics, Inc.
- filed_at: 2025-11-28T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/876343/000119312525302552/0001193125-25-302552-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/876343/000119312525302552/lctx-20251128.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-302552
- JSON: https://secwatch.observer/filing/0001193125-25-302552.json
- Plain text: https://secwatch.observer/filing/0001193125-25-302552.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.